Authors: ROGERS RL JAVED TA BOSS RE VIRELLA G STUART RK FREILAHR D

Citation: Rl. Rogers et al., TRANSFUSION MANAGEMENT OF AN IGA DEFICIENT PATIENT WITH ANTI-IGA AND INCIDENTAL CORRECTION OF IGA DEFICIENCY AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION, American journal of hematology, 57(4), 1998, pp. 326-330

Authors: FREILAHR D KOVACS CC ODONOGHUE N LANZA K SCHAUB C LIMA CMR DUNLAP D STUART RK

Citation: D. Freilahr et al., PILOT PROGRAM FOR OUTPATIENT ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT), Blood, 88(10), 1996, pp. 1633-1633

Authors: HALL PD FREILAHR D STUART RK

Citation: Pd. Hall et al., A PHASE I-II TRIAL OF GRANISETRON FOR PREVENTION OF NAUSEA AND VOMITING IN PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE (HDCY) REGIMENS FOLLOWED BY STEM-CELL TRANSPLANTATION, Blood, 88(10), 1996, pp. 1650-1650

Authors: HALL P FREILAHR D GOULET J SAHOVIC E STUART R

Citation: P. Hall et al., THE COMBINATION OF PENTOXIFYLLINE (P) AND CIPROFLOXACIN (C) DOES NOT DECREASE THE TOXICITY OF BONE-MARROW TRANSPLANTATION (BMT), Blood, 84(10), 1994, pp. 10000492-10000492